非鸦片类止痛药市场－全球产业规模、份额、趋势、机会和预测：按产品、治疗用途、分销管道、地区和竞争格局划分，2021-2031年

全球非鸦片类止痛药市场预计将从 2025 年的 8.3632 亿美元成长到 2031 年的 10.8349 亿美元，复合年增长率为 4.41%。

这些药物，包括对乙酰胺酚、非类固醇消炎剂（NSAIDs）和局部麻醉剂，能够在不与鸦片受体相互作用的情况下缓解疼痛。由于慢性疼痛负担日益加重，以及为缓解鸦片类药物危机而采取的严格监管措施，这项特性变得愈发重要。美国医学会（AMA）的数据也支持这种转向更安全治疗方案的趋势。该机构预测，到2024年，全美阿片类处方笺将比2012年下降51.7%，显示人们正显着转向使用非鸦片类药物。

儘管存在这些积极趋势，但市场仍面临与当前标准疗法安全性相关的重大挑战，尤其是长期使用带来的心血管和消化器官系统风险。这些副作用限制了需要长期照护的患者的治疗选择，从而有效地缩小了潜在市场规模。此外，监管机构实施严格的证据标准，要求新化合物必须展现出卓越的安全性，这设定了很高的进入门槛，减缓了该领域新治疗方法的引入和推广。

市场驱动因素

全球对无鸦片类药物疼痛管理通讯协定的重视正从根本上重塑竞争格局。医疗系统正积极推行管理方案，以更安全的替代疗法取代成瘾性麻醉止痛药。这一策略转变促使药物研发领域的资本投入激增，例如，Latigo Biotherapeutics公司在2024年2月完成的A轮资金筹措，筹集了1.35亿美元，用于推进其下一代非鸦片类候选药物的研发。这项投资旨在应对一项紧迫的临床挑战，进一步凸显了开发有效、无成瘾性治疗方案的紧迫性。正如Vertex Pharmaceuticals公司在2024年7月的报告中所指出的，「美国每年约有8,000万人需要服用急性疼痛药物」。

同时，慢性疼痛和关节炎的日益普遍正在推动市场扩张，而全球人口老化加剧了这一趋势，老年人更容易患上与老龄化相关的退化性肌肉骨骼疾病和神经病变疾病。这些疾病需要长期消化器官系统和传统非类固醇消炎剂（NSAIDs）的胃肠道风险。 2024年11月《MedPage Today》的一篇报导引用的一项调查数据表明了这种需求的规模，该文章报告称，2023年美国成年人中将有24.3%的人患有慢性疼痛。这确保了对能够提供持久疗效的创新止痛药的持续需求。

市场挑战

全球非鸦片类镇痛药市场成长的主要障碍在于现有标准疗法长期使用所带来的安全隐患。儘管临床上迫切需要摆脱鸦片类药物，但长期使用关键药物类别（尤其非类固醇消炎剂)）已被证实存在严重的消化道出血和心血管事件风险，这限制了市场扩张。这些安全隐患迫使医疗机构严格限制剂量和处方疗程，实际上将许多老年患者和合併其他疾病的患者排除在持续疼痛管理之外。这种做法人为地限制了市场规模，而限制因素并非疗效需求，而是药物毒性。

近期临床证据进一步强化了这种限制性环境，凸显了这些风险，并鼓励谨慎用药。例如，欧洲风湿病学会 (EARA) 在 2024 年报告称，慢性病患者接受高剂量非类固醇抗发炎药物 (NSAID) 治疗会使心血管疾病风险增加 10%。这些数据不仅限制了病患的用药途径，也提高了参与企业的监管门槛，迫使他们投入大量成本来证明其新化合物相比现有风险具有更优的长期安全性。

市场趋势

选择性NaV1.8钠通道阻断剂的商业化正在建立新的临床标准，其作用标靶为週边疼痛讯号，同时避免了阿片类药物典型的中枢神经系统副作用。这项药物创新直接满足了市场对强效镇痛药的需求，既避免了麻醉性镇痛药的依赖性风险，也避免了传统非类固醇抗发炎药的出血风险。该类药物的疗效已得到患者良好疗效的证实。根据Vertex Pharmaceuticals 2024年1月发布的新闻稿，在一项3期临床研究中，83.2%的患者对选择性NaV1.8抑制剂苏泽曲啶（suzetridine）治疗中重度急性疼痛的疗效评价为「良好」、「非常好」或「极佳」。

同时，经皮和局部给药系统正变得越来越受欢迎。它们能够局部缓解疼痛，同时避免口服给药带来的全身毒性。医疗保健提供者越来越倾向于使用这些製剂治疗神经病变疼痛和肌肉骨骼疾病，以降低前述的心血管和消化器官系统风险，有助于提高老年人的长期用药依从性。 Scilex Holding Company 的Lidocaine局部给药系统自 2024 年 2 月上市以来已治疗超过一百万名患者，其高普及率也印证了这一转变。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球非鸦片类止痛药市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（医用大麻、含薄荷醇、 Omega-3脂肪酸、肉毒桿菌、辣椒素衍生物）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美非鸦片类镇痛药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲非鸦片类镇痛药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区非鸦片类镇痛药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲非鸦片类镇痛药市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲非鸦片类止痛药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球非鸦片类止痛药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Vertex Pharmaceuticals Inc.
• Cadence Pharmaceuticals Inc.
• Pacira Biosciences Inc.
• Eli Lilly and Company
• Centrexion Therapeutics Corp.
• Biogen Inc.
• Novartis AG
• GSK PLC
• Pfizer Inc.
• Teikoku Seiyaku Co. Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Non-Opioids Analgesics Drugs Market is projected to expand from USD 836.32 Million in 2025 to USD 1083.49 Million by 2031, exhibiting a compound annual growth rate of 4.41%. These pharmacological agents, which include acetaminophen, NSAIDs, and local anesthetics, provide pain relief without interacting with opioid receptors, a characteristic that has become increasingly critical due to the rising burden of chronic pain and strict regulatory efforts to mitigate the opioid crisis. This shift toward safer therapeutic options is evidenced by data from the American Medical Association, which reported a 51.7% nationwide decrease in opioid prescriptions in 2024 compared to 2012 levels, indicating a significant migration toward non-opioid pharmacotherapies.

Despite these positive drivers, the market encounters substantial hurdles related to the safety profiles of current standard treatments, particularly the cardiovascular and gastrointestinal risks associated with long-term use. These adverse effects constrain the therapeutic window for patients needing prolonged care, effectively limiting the total addressable market. Furthermore, regulatory bodies enforce rigorous evidentiary standards requiring new compounds to demonstrate superior safety, creating high barriers to entry that slow the introduction and expansion of novel therapies within the sector.

Market Driver

The competitive landscape is being fundamentally reshaped by a global emphasis on opioid-free pain management protocols, where healthcare systems are aggressively implementing stewardship programs to replace addictive narcotics with safer alternatives. This strategic pivot is fueling a surge in capital allocation for drug discovery, as highlighted by Latigo Biotherapeutics securing $135 million in Series A financing in February 2024 to advance next-generation non-opioid candidates. This investment addresses an urgent clinical gap, further underscored by a July 2024 Vertex Pharmaceuticals report noting that approximately 80 million people in the U.S. require acute pain medication annually, creating a critical imperative for effective, non-addictive therapeutic options.

Concurrently, the increasing prevalence of chronic pain and arthritic conditions serves as a demographic engine for market expansion, driven by an aging global population prone to degenerative musculoskeletal and neuropathic disorders. These conditions necessitate long-term pharmacological interventions that avoid the toxicity of opioids or the gastrointestinal risks of traditional NSAIDs. The scale of this demand is illustrated by surveillance data cited in a November 2024 MedPage Today article, which revealed that 24.3% of U.S. adults reported suffering from chronic pain in 2023, ensuring a continuous need for innovative analgesics capable of delivering sustained efficacy.

Market Challenge

A primary obstacle inhibiting the growth of the global non-opioid analgesics drugs market is the unfavorable safety profile linked to the chronic administration of existing standard-of-care treatments. While there is a clinical urgency to move away from opioids, market expansion is restricted because dominant drug classes, particularly NSAIDs, carry documented risks of severe gastrointestinal bleeding and cardiovascular events when used long-term. These safety concerns force providers to strictly limit dosage and prescription duration, effectively excluding a significant population of elderly and comorbid patients from consistent pain management, thereby artificially capping the market volume based on toxicity rather than efficacy demand.

This restrictive environment is reinforced by recent clinical evidence that highlights these risks and promotes cautious prescribing behaviors. For instance, the European Alliance of Associations for Rheumatology reported in 2024 that high-dose NSAID regimens were associated with a 10% increased risk of cardiovascular disease in patients treated for chronic conditions. Such data not only limits patient access but also elevates the regulatory barriers for new entrants, who must incur substantial costs to prove that their novel compounds offer superior long-term safety compared to these established risks.

Market Trends

The commercialization of selective NaV1.8 sodium channel blockers is establishing a new clinical standard by targeting peripheral pain signals while avoiding the central nervous system side effects typical of opioids. This pharmacological innovation directly addresses the market's need for potent analgesia that bypasses the addiction risks of narcotics and the bleeding liabilities of traditional NSAIDs. The viability of this class is supported by strong patient outcomes; according to a January 2024 Vertex Pharmaceuticals press release, 83.2% of patients in a Phase 3 study rated the selective NaV1.8 inhibitor suzetrigine as good, very good, or excellent for treating moderate-to-severe acute pain.

Simultaneously, the market is witnessing a proliferation of transdermal and topical drug delivery systems, which offer localized pain relief that circumvents the systemic toxicity associated with oral administration. Healthcare providers are increasingly favoring these formulations for neuropathic and musculoskeletal conditions to mitigate the cardiovascular and gastrointestinal risks mentioned previously, thereby supporting better long-term compliance in elderly populations. This shift is evidenced by significant adoption rates, such as Scilex Holding Company's February 2024 announcement that over one million patients have been treated with their lidocaine topical system since its launch.

Key Market Players

• Vertex Pharmaceuticals Inc.
• Cadence Pharmaceuticals Inc.
• Pacira Biosciences Inc.
• Eli Lilly and Company
• Centrexion Therapeutics Corp.
• Biogen Inc.
• Novartis AG
• GSK PLC
• Pfizer Inc.
• Teikoku Seiyaku Co. Ltd.

Report Scope

In this report, the Global Non-Opioids Analgesics Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Opioids Analgesics Drugs Market, By Products

• Medical Cannabis
• Menthol- Containing
• Omega 3 Fatty Acid
• Botulinum Toxins
• Capsaicin Derived

Non-Opioids Analgesics Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Opioids Analgesics Drugs Market.

Available Customizations:

Global Non-Opioids Analgesics Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Opioids Analgesics Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Products (Medical Cannabis, Menthol- Containing, Omega 3 Fatty Acid, Botulinum Toxins, Capsaicin Derived)
  • 5.2.2. By Region
  • 5.2.3. By Company (2025)
• 5.3. Market Map

6. North America Non-Opioids Analgesics Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Products
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Opioids Analgesics Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Products
  • 6.3.2. Canada Non-Opioids Analgesics Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Products
  • 6.3.3. Mexico Non-Opioids Analgesics Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Products

7. Europe Non-Opioids Analgesics Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Products
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Opioids Analgesics Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Products
  • 7.3.2. France Non-Opioids Analgesics Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Products
  • 7.3.3. United Kingdom Non-Opioids Analgesics Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Products
  • 7.3.4. Italy Non-Opioids Analgesics Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Products
  • 7.3.5. Spain Non-Opioids Analgesics Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Products

8. Asia Pacific Non-Opioids Analgesics Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Products
  • 8.2.2. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Opioids Analgesics Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Products
  • 8.3.2. India Non-Opioids Analgesics Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Products
  • 8.3.3. Japan Non-Opioids Analgesics Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Products
  • 8.3.4. South Korea Non-Opioids Analgesics Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Products
  • 8.3.5. Australia Non-Opioids Analgesics Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Products

9. Middle East & Africa Non-Opioids Analgesics Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Products
  • 9.2.2. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Opioids Analgesics Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Products
  • 9.3.2. UAE Non-Opioids Analgesics Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Products
  • 9.3.3. South Africa Non-Opioids Analgesics Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Products

10. South America Non-Opioids Analgesics Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Products
  • 10.2.2. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Opioids Analgesics Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Products
  • 10.3.2. Colombia Non-Opioids Analgesics Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Products
  • 10.3.3. Argentina Non-Opioids Analgesics Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Products

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Opioids Analgesics Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Vertex Pharmaceuticals Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cadence Pharmaceuticals Inc.
• 15.3. Pacira Biosciences Inc.
• 15.4. Eli Lilly and Company
• 15.5. Centrexion Therapeutics Corp.
• 15.6. Biogen Inc.
• 15.7. Novartis AG
• 15.8. GSK PLC
• 15.9. Pfizer Inc.
• 15.10. Teikoku Seiyaku Co. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer